Abstract:Abstract Background Diffuse large-B-cell lymphoma (DLBCL) is the most frequent type of lymphoma which accounts for about 40 percent of new cases of lymphoma and more than 80 percent of aggressive lymphomas. It is reported to represent approximately 60 percent of all B-cell lymphomas in Eastern Asia and more than half of patients with DLBCL were found over 60 years old. The current first-line therapy is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) combined with Rituximab. However, positive effects of Rituximab use in the elderly were not certain before the year 2002 when clinical trials proved that it was more effective with Rituximab. However, the addition of Rituximab has brought more toxicities, thus a better medical care to prevent toxicities and weighing over toxicities and benefits should be carefully done before initiation of the RCHOP regimen in the elderly. It has been recognized now that DLBCL is a heterogeneous disease with different molecular characteristics, such as the germinal center B-cell (GCB) and non-GCB subtypes. Though both commonly seen in both Asia and the West, DLBCL has been reported to differ in some molecular characteristics. Studies revealed differences in the proportion of GCB and non-GCB DLBCL between Asian and Western patients. Whether this difference contributes to clinical treatment and response to the current RCHOP regimen still remains controversial. An overall similar outcome was observed in DLBCL elderly patients from both East Asia and West treated with RCHOP. However, more data is needed to determine the GC proportion, the benefits and toxicity files of RCHOP in Asian population. Materials and Methods A total of 84 elderly DLBCL patients who are 60 years old or older admitted to our center between 2009 and 2013 were included. Among them, 48 received CHOP with Rituximab and 36 received CHOP only chemotherapy due to economic reasons. No significant differences in gender, age distribution were found between the two groups. We stopped follow-up of these patients till May 2013. Overall survival time (OS), progression free survival time (PFS), GCB subtypes and toxicity files after chemotherapy were recorded. To better assess the stratification of IPI, we grouped these patients based on IPI score in two: IPI 0-1; 2; 3; 4-5 and IPI 0-2; 3-5. Cox-regression was performed for GCB subtypes, chemotherapy, different IPI groups, extranodal involvement with OS or PFS using SPSS 16.0 software. Kaplan-Meier survival curves also plotted between different factors with PFS or OS. P value less than 0.05 was considered significant. Results In the four-group IPI scoring stratification system, the Cox regression model demonstrated a longer OS and PFS in Chinese elderly DLBCL patients treated with RCHOP than those receiving CHOP alone (p=0.014 and p<0.001). OS did not differ with GCB subtypes, extranodal involvement and the four IPI groups. PFS did not show difference with GCB subtypes, extranodal involvement, however, demonstrated an advantage in IPI group 1 (IPI=0 or 1) and group 2 (IPI=2). In the two-group IPI scoring stratification system, results showed a longer OS and PFS in patients treated with RCHOP (p=0.007 and p<0.001) and in patients with an IPI score less than 3 (p=0.002 and p=0.008). OS and PFS still did not differ with GCB subtypes, extranodal involvement. The estimated OS in these Chinese elderly DLBCL patients were 34.2 and 47.2 months in CHOP only group and RCHOP group while the PFS were 17.1 and 33.8 months respectively. 56% of the patients receiving RCHOP relapsed, but only 33% remission rate in CHOP only patients (p=0.048). Toxicities are more commonly seen in patients receiving RCHOP (p=0.013) including febrile neutropenia, infections, interstitial pneumonia and cardiomyopathy. Two patients receiving RCHOP even died with severe infection. Conclusion In the Chinese elderly patients diagnosed with DLBCL, IPI score can predict the OS and PFS when it is stratified into two group (0-2; 3-5). RCHOP use achieved longer OS and PFS than CHOP only regimen. No significant differences were observed in whether the patients have extranodal involvement or GCB subtype. However, Rituximab brought an increased risk of toxicities. In conclusion, Chinese elderly DLBCL patients achieved a longer OS and PFS with RCHOP than CHOP only regimen. However, clinicians should be aware of the toxicities which came along. Disclosures: No relevant conflicts of interest to declare.

[Clinical Comparison of CHO Regimen Versus CHOP Regimen for Treatment of Patients with Intermediate-Grade Non-Hodgkin's Lymphoma].

[Comparison Between R-CHOP Regimen and CHOP Regimen in Treating Naive Diffuse Large B-cell Lymphoma in China--a Multi-Center Randomized Trail].

[Treatment Outcome Analysis of CTOP or CHOP Regimen in Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Patients-Results of a Prospective, Open, Randomized, Multicenter Clinical Trial].

[Comparison of HyperCVAD Regimen and CHOP Regimen in Treating Patients with Lymphoblastic Lymphoma].

The Comparison Between CHOP or ECHOP Regimens in Therapeutic Effect on Diffuse Large B Cell Non-Hodgkin's Lymphoma

Chop Compared to Thp-Cop Regimen: Long-Term Outcome in Chinese Non-Hodgkin Lymphoma (nhl) Patients

Curative Effect Comparison of B-CHOP and CHOP Regimens on Elderly Patients with Recurrent Mantle Cell Lymphoma

Clinical Randomized Comparative Trial of ProMACE-CytaBOM Regimen and CHOP Regimen in Treating Non-Hodgkin's Lymphoma

Comparing CVDLP with CHOP in Induction Treatment for Patients with Advanced Lymphoblastic Lymphoma

Clinical Efficacy of Combination of Rituximab Plus CHOP Scheme for Non-Hodgkin's Lymphoma

Clinical Analysis of Hyper-CVAD/MA Regimen and CHOP/CHOP-like Regimen in the Treatment of 78 Patients with Peripheral T-cell Lymphoma, Not Otherwise Specified (PT-CL-NOS)

Comparison of Zuberitamab Plus CHOP Versus Rituximab Plus CHOP for the Treatment of Drug-Naïve Patients Diagnosed with CD20-positive Diffuse Large B-cell Lymphoma: a Phase 3 Trial

[Comparing CHOP, CHOP+HD-MTX,and BFM-90 Regimens in the Survival Rate of Children and Adolescents with B Cell Non-Hodgkin's Lymphoma].

A Clinical Study of Rituximab Combined with CHOP in Treatment of B Cell Non-Hodgkins Lymphoma

[Evaluation of the Impact of R-CHOP Chemotherapy on Efficacy, Safety and Prognosis in Newly Diagnosed Diffuse Large B-cell Lymphoma Patients and Its Prognostic Impact: a Multicenter Retrospective Study with Long Term Follow-Up].

Efficacy of Rituximab Combined with CHOP for B Cell Non-Hodgkin's Lymphoma

[Clinical Outcomes of 106 Patients with Peripheral T-cell Lymphoma Treated by Standard CHOP Regimen].

A Retrospective Study of the CHOP, CHOPE, and CHOPE/G Regimens As the First-Line Treatment of Peripheral T-cell Lymphomas

Efficacy and Safety Comparison Between R-CHOP and Modified NHL-BFM-90 Regimens in Children and Adolescents with Diffuse Large B-cell Lymphoma

Clinical Outcome Of R-CHOP Or CHOP Regimen For Elderly Patients With Diffuse Large B-Cell Lymphoma In China：A Single Center's Experience

[Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma]